Parallel Advisors’s Oncternal Therapeutics, Inc. Common Stock ONCT Stock Holding History

Parallel Advisors’s Portfolio ONCT Stock Details ONCT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-14	Closed	–	–	2773
2020 Q1	$0	Hold	14	–	–	﹤0.01%	2721
2019 Q4	$1K	Hold	14	–	–	﹤0.01%	2368
2019 Q3	$1K	Hold	14	–	–	﹤0.01%	2347
2019 Q2	$2K	Hold	14	–	–	﹤0.01%	2140
2019 Q1	$2K	Hold	14	–	–	﹤0.01%	2126
2018 Q4	$1K	Hold	14	–	–	﹤0.01%	2078
2018 Q3	$3K	Hold	14	–	–	﹤0.01%	1949
2018 Q2	$30K	Hold	14	–	–	﹤0.01%	908
2018 Q1	$36K	Buy	+14	New	+$31.2K	0.01%	819
2017 Q4	–	Hold	0	–	–	–	2155
2017 Q3	–	Hold	0	–	–	–	2252
2017 Q2	–	Hold	0	–	–	–	2236
2017 Q1	–	Hold	0	–	–	–	2104
2016 Q4	–	Hold	0	–	–	–	1802

Other funds holding ONCT

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Creative Planning Overland Park, Kansas $147B AUM 18.73% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Dowling & Yahnke San Diego, California $2.15B AUM 10.82% 1-Year Est. Return

UCFA

United Capital Financial Advisors Irving, Texas $16.3B AUM 16.34% 1-Year Est. Return

IEQ Capital Foster City, California $21.5B AUM 75.26% 1-Year Est. Return

AAM

Aureus Asset Management Boston, Massachusetts $1.5B AUM 20.3% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Parallel Advisors's ONCT Position: Q2 2020 in Review

Parallel Advisors sold out of Oncternal Therapeutics, Inc. Common Stock (ONCT) in Q2 2020, closing a stake of 14 shares.

Parallel Advisors first reported a position in ONCT in Q1 2018 and held it in 9 quarters. The position peaked at $36K in Q1 2018. 20 funds tracked by Wall St. Rank hold ONCT as of Q2 2020.

Parallel Advisors reported no remaining Oncternal Therapeutics, Inc. Common Stock position as of Q2 2020 after selling out during the quarter.
Parallel Advisors sold 14 Oncternal Therapeutics, Inc. Common Stock shares in Q2 2020.
Parallel Advisors first reported a position in Oncternal Therapeutics, Inc. Common Stock in Q1 2018 and held it in 9 quarters.
Parallel Advisors's Oncternal Therapeutics, Inc. Common Stock position peaked at $36K in Q1 2018.
20 funds tracked by Wall St. Rank held Oncternal Therapeutics, Inc. Common Stock as of Q2 2020.

Based on Parallel Advisors's 13F filing for Q2 2020, filed 16 Jul 2020.